Strategies to prevent intraoperative lung injury during cardiopulmonary bypass.
During open heart surgery the influence of a series of factors such as cardiopulmonary bypass (CPB), hypothermia, operation and anaesthesia, as well as medication and transfusion can cause a diffuse trauma in the lungs. This injury leads mostly to a postoperative interstitial pulmonary oedema and abnormal gas exchange. Substantial improvements in all of the above mentioned factors may lead to a better lung function postoperatively. By avoiding CPB, reducing its time, or by minimizing the extracorporeal surface area with the use of miniaturized circuits of CPB, beneficial effects on lung function are reported. In addition, replacement of circuit surface with biocompatible surfaces like heparin-coated, and material-independent sources of blood activation, a better postoperative lung function is observed. Meticulous myocardial protection by using hypothermia and cardioplegia methods during ischemia and reperfusion remain one of the cornerstones of postoperative lung function. The partial restoration of pulmonary artery perfusion during CPB possibly contributes to prevent pulmonary ischemia and lung dysfunction. Using medication such as corticosteroids and aprotinin, which protect the lungs during CPB, and leukocyte depletion filters for operations expected to exceed 90 minutes in CPB-time appear to be protective against the toxic impact of CPB in the lungs. The newer methods of ultrafiltration used to scavenge pro-inflammatory factors seem to be protective for the lung function. In a similar way, reducing the use of cardiotomy suction device, as well as the contact-time between free blood and pericardium, it is expected that the postoperative lung function will be improved.
Apostolakis
Efstratios E
EE
Department of Cardiothoracic Surgery, University of Patras, School of Medicine, Patras, Greece.
Koletsis
Efstratios N
EN
Baikoussis
Nikolaos G
NG
Siminelakis
Stavros N
SN
Papadopoulos
Georgios S
GS
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000494:pharmacology; D007611:Aprotinin / Q000008:administration & dosage / Q000494:pharmacology; D002315:Cardiopulmonary Bypass / Q000379:methods*; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage; D047549:Coronary Artery Bypass, Off-Pump / Q000009:adverse effects* / Q000379:methods; D006438:Hemodilution / Q000009:adverse effects; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007431:Intraoperative Complications / Q000517:prevention & control*; D047589:Leukocyte Reduction Procedures; D055370:Lung Injury / Q000517:prevention & control*; D012121:Respiration, Artificial / Q000379:methods; D014462:Ultrafiltration / Q000379:methods
D000305:Adrenal Cortex Hormones; D020099:Coated Materials, Biocompatible; D006493:Heparin; D007611:Aprotinin